FimmCyte

UZH Life Sciences Fund

Navignostics

Occlufit

Novartis Venture Fund

FimmCyte develops a novel immune system-based treatment, which demonstrated positive results through early preclinical studies.

Our mission is to identify the ideal treatment to battle each cancer patient’s disease and reduce suffering throughout their journey. At Navignostics we characterize tumors using spatial single-cell proteomics. We use our unique capabilities to identify a cancer treatment that will optimally fight each patient’s tumor. We also accelerate cancer drug development by providing key insights into drug mechanisms and tumor features for companion diagnostic development. Our highly robust and reliable technology and our leading data analytics position us ideally to enable precision cancer diagnostics for patients and to provide services to pharma and biotech partners. This way we help people suffering from cancer by making more drugs available and by finding the right one for every patient.

Occlufit is an occluder device that conforms to complex geometries and provides immediate sealing of cardiovascular defects.

ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.

CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.

The UZH Life Sciences Fund involves two equal partners: the UZH Foundation and the Novartis Venture Fund. It seeks donations from private individuals, foundations and companies for the strategic priorities of the University of Zurich.

UZH Life Sciences Fund

Portfolio

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless